Overview

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Status:
RECRUITING

Trial end date:
2028-05-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.

Phase:

PHASE3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

mirikizumab
Tirzepatide